Log in

ETR:BIOBiotest Stock Price, Forecast & News

€22.60
+0.60 (+2.73 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
€21.60
Now: €22.60
€22.60
50-Day Range
€18.00
MA: €21.27
€22.80
52-Week Range
€17.20
Now: €22.60
€24.40
Volume1,931 shs
Average Volume1,927 shs
Market Capitalization$447.16 million
P/E RatioN/A
Dividend Yield0.19%
BetaN/A
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; and Vihuma for treating haemophilia A acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company's products under development include BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.
Read More
Biotest logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.79 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-6103-8010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$419.10 million
Cash Flow€1.90 per share
Book Value€12.05 per share

Profitability

Miscellaneous

Employees1,663
Market Cap$447.16 million
Next Earnings DateN/A
OptionableOptionable

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Biotest (ETR:BIO) Frequently Asked Questions

How has Biotest's stock been impacted by COVID-19 (Coronavirus)?

Biotest's stock was trading at €18.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIO stock has increased by 22.8% and is now trading at €22.60. View which stocks have been most impacted by Coronavirus.

Has Biotest been receiving favorable news coverage?

News articles about BIO stock have trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Biotest earned a news impact score of -4.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutBiotest.

Who are some of Biotest's key competitors?

What other stocks do shareholders of Biotest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotest investors own include GRIFOLS S A/S (GRFS), CSL (CSL) and ADMA Biologics (ADMA).

Who are Biotest's key executives?

Biotest's management team includes the following people:
  • Dr. Bernhard R. M. Ehmer, Chairman of Management & CEO (Age 64)
  • Dr. Michael Ramroth, CFO, Head of Fin.s & Central Services and Member of the Board of Management
  • Dr. Georg Floß, COO & Member of the Board of Management
  • Dr. Monika Buttkereit, Head of Investor Relations
  • Dr. Christina Erb, Head of Corp. HR

What is Biotest's stock symbol?

Biotest trades on the ETR under the ticker symbol "BIO."

What is Biotest's stock price today?

One share of BIO stock can currently be purchased for approximately €22.60.

How big of a company is Biotest?

Biotest has a market capitalization of $447.16 million and generates $419.10 million in revenue each year. Biotest employs 1,663 workers across the globe.

What is Biotest's official website?

The official website for Biotest is www.biotest.com.

How can I contact Biotest?

Biotest's mailing address is Landsteinerstr. 5, DREIEICH, 63303, Germany. The company can be reached via phone at +49-6103-8010.

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.